← SynDRA
ADAGRASIB
SynDRA canonical compound SYN0040002 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | KRAS |
|---|
| Mechanism of action | ras gtpase inhibitor |
|---|
| Indication | gastric adenocarcinoma |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- KRAS INHIBITOR
- GTPase KRas inhibitor
- ras gtpase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- AURKA
- BRD4
- BRPF1
- BTK
- CDK2
- CSNK1D
- FGFR3
- GSK3B
- KARS1
- MAPK1
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- KRAZATI
- Krazati
- krazati
- MRTX849
- KRAS G12C INHIBITOR MRTX849
- MRTX-849
- ADAGRASIB (MRTX849)
- COMPOUND 20
- MRTX 849
- UNII-8EOO6HQF8Y
- 8EOO6HQF8Y
- CHEMBL4594350
- SCHEMBL20974691
- GTPL10888
- Kras G12C inhibitor MRTX849
- BCP31538
- EX-A3258
- MFCD32263433
- s8884
- compound 20 [PMID: 32250617]
- BS-16211
- HY-130149
- CS-0105265
- RefChem:56312
- DTXCID001767019
- Adagrasib [USAN]
- Adagrasib (MRTX849)
- Krazati (TN)
- ADAGRASIB [INN]
- Adagrasib (USAN/INN)
- MRTX849(Adagrasib)?
- ADAGRASIB [WHO-DD]
- C32H35ClFN7O2
- orb1298993
- SCHEMBL29349856
- SCHEMBL29423703
- SCHEMBL29979738
- CHEBI:233309
Look up ADAGRASIB in the interactive SynDRA portal →